Skip to Content

A Novel Neurostimulation Solution for a Highly Prevalent, Poorly Treated Form of Obstructive Sleep apnea

Team Members:
  • Shri Prabha Shivram
  • Phoebe Dijour
  • Anders Sideris
  • Mitch Turley
  • Dr. Kevin Motz
  • Dr. Alan Schwartz
  • Dr. Stuart Mackay
  • Dr. Robson Capasso
  • Dr. Youseph Yazdi
  • Dr. Soumyadipta Acharya
  • Dr. April Zambelli-Weiner
  • Dr. Nicholas Rowan
  • Dr. Ashish Nimgaonkar
  • Antony Fuleihan


Complete upper airway collapse is a severe form of obstructive sleep apnea affecting 300 million people worldwide, and 16 million people in the US alone. It is marked by repeated upper airway collapse that disrupts breathing during sleep. Left untreated, this disease doubles the risk of stroke, heart attack, diabetes, and dramatically increases excessive sleepiness, and impaired daytime function. The few treatment options currently available are expensive, invasive, and have poor outcomes.

SomnOSA provides the solution— A novel neurostimulation oral appliance prevents obstruction using a proprietary therapy delivery system. Our platform is a non invasive treatment, both highly effective and affordable. SomnOSA provides a comfortable and reliable treatment for severe sleep apnea, to restore restful sleep, one breath at a time.


Read the Johns Hopkins University privacy statement here.